XXB 750

Add links
From Wikipedia, the free encyclopedia

XXB 750 is an experimental injected drug that targets natriuretic peptide (NPR1) and is developed to treat resistant hypertension.[1][2] It was also tried for heart failure with reduced ejection fraction.[3]

References[edit]

  1. ^ Janakiraman, Arun; Cohen, Debbie L. (27 September 2023). "New Potential Treatments for Resistant Hypertension". Current Cardiology Reports. doi:10.1007/s11886-023-01966-8.
  2. ^ "XXB 750 - AdisInsight". adisinsight.springer.com. Retrieved 23 November 2023.
  3. ^ "Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)". Retrieved 23 November 2023.
Retrieved from "https://en.wikipedia.org/w/index.php?title=XXB_750&oldid=1190951357"